Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 1, 2013, Pages 58-61

  Maimaiti, Rena ^a   Zhang, Yuexin ^a   Pan, Kejun ^a   Wubuli, Maimaiti ^a   Andersson, Rune ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

HBV; HCV; HIV

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON; RIBAVIRIN; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS HEPATITIS;

ADULT; CHINA; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; LIVER FUNCTION TESTS; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84877914314     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109712446176     Document Type: Article

References (28)

1. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history, therapeutic options and clinical management. Infection. 2004;32(1):33-46.
2. Sterling RK, Sulkowski MS. Hepatitis C virus in the setting of HIV or Hepatitis B virus coinfection. Semin Liver Dis. 2004; 24(suppl 2):61-68.
3. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis. 2001;183(7):1112-1115.
4. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100(5):1584-1589.
5. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350(9089):1425-1431.
6. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related compensated cirrhosis. Hepatology. 2005;41(4):779-789.
7. Merchante N, Jiménez-Saenz M, Pineda JA. Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev. 2007;9(3):131-139.
8. Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related endstage liver disease. AIDS. 2006;20(1):49-57.
9. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-569.
10. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-472.
11. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303-1310.
12. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004; 53(5):744-749.
13. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon a-2a and ribavirin. J Viral Hepat. 2006;13(11):762-769.
14. Girón-González JA, Brun F, Terron A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicenter study. Antivir Ther. 2007;12(6):899-907.
15. Bruno R, Sacchi P, Puoti M, et al. Natural history of compensated viral cirrhosis in a cohort of patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 2007; 46(3):297-303.
16. Yuan P. Grading Standards of Child-Pugh. Chin J Hepatol. 1999; 7(4):254.
17. Osborn MK, Guest JL, Rimland D. Hepatitis B virus and HIV co infection: relationship of different serological patterns to survival and liver disease. HIV Med. 2007;8(5):271-279.
18. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45(9): 1221-1229.
19. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis. 2007;45(5):624-632.
20. van Bommel F, Wunsche T, Mauss S, et al. Comparaison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40(6):1421-1425.
21. van Bjmmel F, Zjllner B, Sarrazin C, Spengler U, Hjppe D, Mjller B. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV-DNA level during adefovir therapy. Hepatology. 2006;44(2):318-325.
22. Van Bjmmel F, Trojan J, Feucht H. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. Hepatology. 2007;46:270 A.
23. Xiaofei G, Qian C, Xiang S, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis. 2011;11:88.
24. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. J HIV Ther. 2003;8(4): 77-84.
25. Dervisevic S, Pillay D. Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection. J HIV Ther. 2003;8(4): 89-95.
26. Zhang RF, Sun HQ, Huang Q, et al. Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients with AIDS. Zhonghua Gan Zang Bing Za Zhi. 2007;15(10): 734-737.
27. Zhang RF, Sun HQ, Huang Q, et al. Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients with AIDS. Zhonghua Gan Zang Bing Za Zhi. 2007;15(10): 734-737.
28. Soriano V, Barreiro P, Martín-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007;195(8):1181-1183.